Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.2%. By the end of trading, Santarus fell $1.08 (-4.3%) to $24.15 on average volume. Throughout the day, 1,474,785 shares of Santarus exchanged hands as compared to its average daily volume of 1,460,900 shares. The stock ranged in price between $24.05-$24.78 after having opened the day at $24.62 as compared to the previous trading day's close of $25.23. Other companies within the Health Care sector that declined today were:

Mast Therapeutics



), down 43.4%,

Escalon Medical Corporation



), down 9.3%,




Scroll to Continue

TheStreet Recommends

), down 7.0% and

Organovo Holdings



), down 5.8%.

Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. Santarus has a market cap of $1.6 billion and is part of the drugs industry. Shares are up 126.4% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Santarus a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

Ambit Biosciences



), up 25.5%,

Horizon Pharma



), up 20.8%,

GW Pharmaceuticals PLC ADR



), up 15.4% and

Ocera Therapeutics



), up 13.0% , were all gainers within the health care sector with

Regeneron Pharmaceuticals



) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.